medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2010, Number 4

<< Back Next >>

Arch Med Fam 2010; 12 (4)

Type 2 Diabetes Mellitus-associated Work Disability: Experience in 393 Patients from Ciudad Juárez, Mexico

Reyes CMT, López ALR, Flores PL

Language: Spanish
References: 24
Page: 110-115
PDF size: 150.16 Kb.


ABSTRACT

Objective: To determine the frequency of disability due to Type 2 diabetes mellitus (T2DM) and complications. Material and Methods: Descriptive and cross-sectional study. We included 393 patients in the study by means of disability opinions with a diagnosis of T2DM. We performed bivariate analysis with EPI-INFO 2000 software. Results: Retinopathy was the most common cause of disability (43.3%). Mean age was 50 years. Women showed a 2.5 times higher risk of neuropathy (χ2, 9.0935) (p = 0.001); patients who were plant operators, machine operators, and assemblers (ISCO group 8.2-88) had 2.6 times the risk of neuropathy (CI 1.4249 – 4.7983; χ2 of 10.1012) (p = 0.015). Males had a 5.5 times greater risk of macroangiopathy (χ2, 18.19) (p = 0.006), and marketing and business salespersons (group 5 of ISCO-88), a 4.5 times greater risk of macroangiopathy (χ2, 16.41) (p= 0.03). A total of 3,785 years of potentially lost work years and 2,941 years of potential life lost were calculated. Conclusions: The chronic complications of T2DM can completely prevent or increase work absenteeism, and productivity may deteriorate in quality and quantity. Temporary-disability workdays are numerous.


REFERENCES

  1. La diabetes es un problema creciente de salud pública. Disponible en: http://www.cdc.gov/diabetes/spanish/glance y htmhttp://www.cdc.gov/diabetes/consumer/index.htm.

  2. Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabetic Medicine. 2004 May. 21(5):403-14.

  3. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004; 27(8):2067-73.

  4. Arredondo A, Zuñiga A. Economic consequences of epidemiological changes in diabetes in middle income countries: the Mexican case. Diabetes Care 2004; 27(1): 104-09.

  5. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J. et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004; 27 Suppl 1:S47-54.

  6. Ibarra Costilla E. Años de vida productivos perdidos por complicaciones crónicas de diabetes mellitus en población económicamente activa. Trabajo de Investigación. Maestría en Salud Pública, Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León (México) 2002.

  7. Salinas Martínez AF, Muñoz Moreno AR, Barraza de León E, Villarreal Ríos GM y cols. Necesidades de Salud del diabético usuario del primer nivel de atención. Salud Pública de México 2001;43 (4): 324-35.

  8. Watkins PJ. The diabetic foot. BMJ. 2003; 326 (7396):977-9.

  9. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. New England Journal Medicine. 2004;351(1):48-55.

  10. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19):2570-81.

  11. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM. Preventive foot care in people with diabetes. Diabetes Care 2000; 21:2161-77.

  12. Palumbo PJ, Melton LJ III. Peripheral vascular disease and diabetes. In: Diabetes in America: diabetes data compiled 1999. Washington, D.C.: Government Printing Office, August 2000.

  13. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. New England Journal of Medicine. 2002; 346(15):1145-51.

  14. Bloomgarden ZT. Diabetic nephropathy. Diabetes Care. 2005;28(3):745-51.

  15. Kamal-Bahl SJ, Pantely S, Pyenson B, Alexander CM. Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease. Preventing Chronic Disease. 2006;3(3):A83.

  16. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28(1):164-76.

  17. Vinik AI, Park TS, Stansberry KB et al. Diabetic neuropathies. Diabetología. 2000; 43:957-73.

  18. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. American Journal Health-System Pharmacy. 2004;61(2):160-73.

  19. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabetic Medicine. 2003;20(2):88-98.

  20. Boletín Epidemiológico 2001; 22 (2). Disponible en: http://www.dgepi.salud.gob.mx/boldiabetes/boletin_dm2.htm

  21. Michael M, Engelgau M, Geiss L, Jinan B, Boyle J, Benjamin S, Gregg E, et al. The Evolving Diabetes Burden in the United States, Ann Intern Med. 2004;140:945-950.

  22. Stefano V, Ferrucci L, Blaum C, Ostir G, Cappola A, et al. Progression of Lower-Extremity Disability in Older Women With Diabetes The Women’s Health and Aging Study. Diabetes Care 2003; 26:70-75.

  23. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, Ganiats TG, Ginsberg HN, Kahn R. et al. Prevention or delay of type 2 diabetes. Diabetes Care. 2004; 27 Suppl 1:S47-54.

  24. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54(1):1-7.




2020     |     www.medigraphic.com